Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Hunt

Showing results (1011-1020 of 1,059) with videos related to

Pageof 106
Sort By:
NEJM Evidence|February 6, 2024
Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy SurgeryBarbara L Smith, Kelly K Hunt, David Carr, et al.
Annals of Surgery|May 27, 2017
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic TherapyHenry M Kuerer, Gaiane M Rauch, Savitri Krishnamurthy, et al.
NPJ Precision Oncology|July 27, 2025
IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancerNicole M Kettner, Tuyen N Bui, Juliana Navarro-Yepes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 StudyPatrick Neven, Nicole Stahl, Maria Vidal, et al.
Cancer|August 28, 2024
Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomesAndrew J Bishop, Devarati Mitra, Ahsan Farooqi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerAman U Buzdar, Nuhad K Ibrahim, Deborah Francis, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
Massively parallel combination screen reveals small molecule sensitization of antibiotic-resistant Gram-negative ESKAPE pathogensMegan W Tse, Meilin Zhu, Benjamin Peters, et al.
International Journal of Cancer|February 7, 2022
Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma centerElise F Nassif, Brandon Cope, Raymond Traweek, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Gut microbiome-dependent IL-1 signaling is a mediator of ACVR1 <sup>R206H</sup> -driven heterotopic ossificationHannah M Herzog, Camille Fang, Liam Lam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2019
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast CancerNicole M Kettner, Smruthi Vijayaraghavan, Merih Guray Durak, et al.
Pageof 106

Showing results (1011-1020 of 1,059) with videos related to

Sort By:
Pageof 106
NEJM Evidence|February 6, 2024
Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy SurgeryBarbara L Smith, Kelly K Hunt, David Carr, et al.
Annals of Surgery|May 27, 2017
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic TherapyHenry M Kuerer, Gaiane M Rauch, Savitri Krishnamurthy, et al.
NPJ Precision Oncology|July 27, 2025
IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancerNicole M Kettner, Tuyen N Bui, Juliana Navarro-Yepes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 StudyPatrick Neven, Nicole Stahl, Maria Vidal, et al.
Cancer|August 28, 2024
Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomesAndrew J Bishop, Devarati Mitra, Ahsan Farooqi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerAman U Buzdar, Nuhad K Ibrahim, Deborah Francis, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
Massively parallel combination screen reveals small molecule sensitization of antibiotic-resistant Gram-negative ESKAPE pathogensMegan W Tse, Meilin Zhu, Benjamin Peters, et al.
International Journal of Cancer|February 7, 2022
Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma centerElise F Nassif, Brandon Cope, Raymond Traweek, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Gut microbiome-dependent IL-1 signaling is a mediator of ACVR1 <sup>R206H</sup> -driven heterotopic ossificationHannah M Herzog, Camille Fang, Liam Lam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2019
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast CancerNicole M Kettner, Smruthi Vijayaraghavan, Merih Guray Durak, et al.
Pageof 106